Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
about
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets.Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.Comparative analysis of package inserts of local and imported antihypertensive medications in Palestine.Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.New and incremental FDA black box warnings from 2008 to 2015.Letter: direct-acting agent therapy and HCV-related Child C cirrhosis.Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.To Report or Not to Report: Exploring Healthy Volunteers' Rationales for Disclosing Adverse Events in Phase I Drug Trials.Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsPsychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and DevelopmentCost recovery by Health Canada and drug safety: a time-series analysis
P2860
Q38623810-903062ED-9A10-461A-A49E-A6D7670D63D9Q38635246-AA22E4DE-77A9-4820-9DA8-CE74A19C96EEQ41616440-453ED5CD-4CE6-4408-A0BB-96F68B289547Q41930643-687EC58F-7DF6-46FB-936E-ED5DC09549B2Q47661976-B31D24FE-9CA0-4240-BE48-63189841C201Q47684959-32E1ECFF-EF88-477A-A9F1-4AC6EEE36FBCQ48125464-B7E3C5EC-94A8-4772-91EE-C83C2ECFF405Q48142490-5C36A8A1-F08A-4D60-B570-AFC9FB99BD0EQ49597042-C29E63AC-A478-4811-A998-5F1138323D5EQ50055809-31028353-2D11-4759-AF66-0891CFF53B94Q52310152-2A7800A7-0A47-486B-A697-9B7CB7107566Q52741009-20F34D79-4552-47FC-8E5C-D0095A5EDB51Q55315206-5728602A-1C25-4D03-ADC8-5BEAFFA92EF6Q57173000-6CCB755D-94DB-43AD-B3E8-6CF535568ACAQ57309250-1D6F31B5-53E3-4189-97EF-B814463947F8Q58594603-41752283-D69A-4416-B5DC-01FA5F494BAF
P2860
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@en
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@nl
type
label
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@en
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@nl
prefLabel
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@en
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@nl
P2093
P2860
P356
P1476
Postmarket Safety Events Among ...... tration Between 2001 and 2010.
@en
P2093
Alison M Pease
Jean-David Zeitoun
Jenerius A Aminawung
Nicholas S Downing
Nilay D Shah
P2860
P304
P356
10.1001/JAMA.2017.5150
P407
P577
2017-05-01T00:00:00Z